Summary
AbbVie Inc. reported strong revenue growth driven by key immunology and neuroscience products in the third quarter of 2025. Net revenues increased by 9.1% year-over-year to $15.8 billion, with international markets showing robust performance. Despite this top-line growth, net earnings saw a significant decline to $186 million from $1.6 billion in the prior year period. This decrease is largely attributable to substantial expenses including acquired IPR&D and milestones ($2.7 billion), an increase in interest expense, and a significant unfavorable change in the fair value of contingent consideration liabilities, which amounted to $776 million in the quarter. The company continues to invest heavily in its pipeline, with R&D expenses remaining a significant cost. Strategic acquisitions and licensing agreements, such as the acquisition of Capstan Therapeutics and the license with Ichnos Glenmark Innovation, highlight AbbVie's commitment to expanding its therapeutic areas, particularly in immunology and neuroscience. While the company faces ongoing legal proceedings and pricing pressures, it maintains a strong liquidity position with substantial cash and equivalents, supported by consistent operating cash flows.
Financial Highlights
56 data points| Revenue | $15.78B |
| Cost of Revenue | $5.30B |
| Gross Profit | $10.47B |
| SG&A Expenses | $3.57B |
| Operating Expenses | $13.87B |
| Operating Income | $1.90B |
| Interest Expense | $739.00M |
| Net Income | $186.00M |
| EPS (Basic) | $0.10 |
| EPS (Diluted) | $0.10 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1Net revenues grew 9.1% to $15.8 billion for Q3 2025, driven by strong performance in Immunology (Skyrizi, Rinvoq) and Neuroscience (Botox Therapeutic, Qulipta).
- 2Net earnings significantly decreased to $186 million from $1.6 billion year-over-year, primarily due to higher acquired IPR&D and milestone expenses ($2.7 billion) and unfavorable changes in contingent consideration.
- 3Acquired IPR&D and milestone expenses surged to $2.7 billion in Q3 2025, largely from the acquisitions of Capstan Therapeutics ($1.9 billion) and Ichnos Glenmark Innovation ($700 million).
- 4Humira's net revenues continued to decline, falling 55.4% year-over-year, reflecting ongoing biosimilar competition.
- 5The company continues to invest in its pipeline, with R&D expenses increasing 9% to $2.3 billion in Q3 2025.
- 6AbbVie announced an increase in its quarterly dividend to $1.73 per share, signaling confidence in future performance and commitment to shareholder returns.
- 7The company's financial position remains strong, with $5.6 billion in cash and equivalents and positive operating cash flows of $13.8 billion for the nine months ended September 30, 2025.